Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
1.
Braz J Infect Dis ; : 104384, 2024 Oct 11.
Artigo em Inglês | MEDLINE | ID: mdl-39401751

RESUMO

BACKGROUND: Liver transplantation is the treatment for many end-stage liver diseases and hepatocellular carcinoma but shortage of available organs poses significant challenge. Many centers have used grafts from donors with positive anti-HBc serology but concerns about potential hepatitis B virus reactivation and de novo hepatitis B infection have raised questions about the safety of this approach. This study aimed to evaluate the survival of liver transplant recipients from anti-HBc-positive-donors and assess the risk of hepatitis B reactivation and de novo hepatitis B. PATIENTS AND METHODS: A retrospective single-center cohort study was conducted from 2002 to 2018, comparing who received grafts from anti-HBc-positive-donors to those from anti-HBc-negative-donors. The primary outcome was survival and description cases of hepatitis B reactivation/de novo hepatitis B. RESULTS: We analyzed 1,111 liver transplants, in which 993 (89 %) received grafts from anti-HBc-negative-donors and 118 (11 %) from anti-HBc-positive-donors. Median age of recipients from anti-HBc-positive donors was 56 years and from anti-HBc-negative donors was of 53 years (p = 0.001). Male sex was predominant in both groups. Factors associated with death in multivariate analysis were retransplantation, early allograft dysfunction, high MELD, recipient over 60 years and female donor. The utilization of grafts from anti-HBc-positive-donors did not increase mortality. The majority of HBV reactivation and de novo hepatitis B occurred in anti-HBc positive recipients. The risk of hepatitis B reactivation/de novo hepatitis B was low and manageable. CONCLUSION: The study supports safety of liver grafts from anti-HBc-positive donors when employing antiviral prophylaxis. These findings contribute to expand donor options and improve patient outcomes.

2.
Ann Hepatol ; 29(1): 101156, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-37758118

RESUMO

INTRODUCTION AND OBJECTIVES: Occult hepatitis B virus (HBV) infection (OBI) is characterised by low levels of hepatitis B virus (HBV) DNA in the blood/liver of patients with negative hepatitis B surface antigen (HBsAg). This study aimed to determine the OBI prevalence and virological characteristics (viral genotypes and HBsAg mutants) in patients with an "anti-HBc only" serological profile. MATERIALS AND METHODS: A total of 24 900 serum samples were routinely screened for hepatitis B markers over a five-year period. All anti-HBc-positive/HBsAg-negative/anti-HBs-negative sera were selected and analysed for the presence of HBV DNA. Mutational analyses of the HBs gene and polymerase gene sequences were performed. RESULTS: 1749 (7.02%) sera were anti-HBc positive, and 113 (0.45%) sera had an "anti-HBc only" serological profile (HBsAg/anti-HBs negative). HBV DNA was detected in 12/113 (10.61%) "anti-HBc only" positive sera, representing 0.048% of all routinely tested samples. Due to extremely low viremia, HBV genome was successfully sequenced in only two sera where subgenotype D3 was confirmed. Mutational analyses of the S gene revealed multiple missense mutations. In addition to the M133I, Y134F, and G145R mutations, already associated with diagnostic escape, we also found nine novel OBI-related S-gene mutations - S136Y, F158L, K160N, E164G, S167L, A168V, L175S, S210I and F212C. CONCLUSIONS: We detected multiple known and novel S gene mutations in 2/12 (16.6%) OBI cases, nevertheless, further studies are required to determine their role in the pathogenesis of OBI. Understanding the frequencies of clinically relevant HBV mutations may contribute to improvement of diagnostic protocols.


Assuntos
Hepatite B Crônica , Hepatite B , Adulto , Humanos , Vírus da Hepatite B/genética , Antígenos de Superfície da Hepatite B , DNA Viral/genética , Prevalência , Croácia/epidemiologia , Hepatite B/diagnóstico , Hepatite B/epidemiologia , Anticorpos Anti-Hepatite B
3.
Viruses ; 15(11)2023 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-38005864

RESUMO

The hepatitis B virus (HBV), comprising of ten genotypes (A-J), has been a silent threat against humanity, constituting a public health problem worldwide. In 2016, the World Health Organization set forth an impressive initiative for the global elimination of viral hepatitis by 2030. As the target date approaches, many nations, particularly in the Latin American region, face challenges in designing and implementing their respective elimination plan. This review aimed to portray the state of knowledge about the epidemiological, molecular, and clinical characteristics of HBV genotype H (HBV/H), endemic to Mexico. PubMed, Scopus, Web of Science, and Google Scholar were searched to compile scientific literature over 50 years (1970-2022). A total of 91 articles were organized into thematic categories, addressing essential aspects such as epidemiological data, risk factors, HBV genotype distribution, HBV mixed infections, clinical characteristics, and vaccination. The prevalence and its associated 95% confidence interval (95% CI) were estimated using the Metafor package in R programming language (version 4.1.2). We provide insights into the strengths and weaknesses in diagnostics and prevention measures that explain the current epidemiological profile of HBV/H. Training, research, and awareness actions are required to control HBV infections in Mexico. These actions should contribute to creating more specific clinical practice guides according to the region's characteristics. Mexico's elimination plan for HBV will require teamwork among the government health administration, researchers, physicians, specialists, and civil society advocates to overcome this task jointly.


Assuntos
Vírus da Hepatite B , Hepatite B , Humanos , Vírus da Hepatite B/genética , México/epidemiologia , Hepatite B/epidemiologia , Hepatite B/prevenção & controle , Antígenos de Superfície da Hepatite B/genética , Genótipo , Prevalência , DNA Viral/genética
4.
Gac Med Mex ; 157(1): 35-40, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34125813

RESUMO

INTRODUCTION: Identification of hepatitis B virus carriers in blood donors is imperative in order to avoid transmission of the disease via blood transfusion. OBJECTIVE: To determine if blood donors with positive results for serological markers HBsAg and anti-HBc were hepatitis B virus DNA carriers. METHODS: 12,745 samples were collected from six Ecuadorian blood banks and analyzed for HBsAg, anti-HBc and anti-HBs infectious markers by automated ELISA. All samples that tested positive for one, two or all three markers were analyzed with molecular techniques to determine the presence of viral DNA. RESULTS: 27.5 % of the samples that were reactive for anti-HBc alone and 100 % of those with positive results for HbsAg and IgM/IgG anti-HBc were identified to contain hepatitis B virus DNA (p = 0.001). CONCLUSIONS: The selection of infection markers, as well as the detection methods define the results. Performing two serological and one molecular test is important in order to identify hepatitis B virus carriers and prevent its transmission.


INTRODUCCIÓN: La identificación de portadores del virus de la hepatitis B en donantes de sangre es imperativo para evitar la transmisión de la enfermedad a través de transfusiones sanguíneas. OBJETIVO: Determinar si los donantes de sangre con resultados positivos en los marcadores serológicos HbsAg y anti-HBc eran portadores del ADN del virus de la hepatitis B. MÉTODOS: Se recolectaron 12 745 muestras de seis bancos de sangre ecuatorianos, las cuales fueron analizadas con pruebas serológicas para identificar marcadores infecciosos de HBsAg, anti-HBc, anti-HBs mediante ELISA automatizada. Todas las muestras positivas para uno, dos o los tres marcadores fueron analizadas con técnica molecular para determinar la presencia del ADN viral. RESULTADOS: Se identificó que 27.5 % de las muestras reactivas solo a anti-HBc y 100 % de las muestras con resultados positivos de HBsAg/anti-HBc-IgM/IgG presentaron ADN del virus de la hepatitis B (p = 0.001). CONCLUSIONES: La elección de los marcadores de infección y los métodos de detección definen los resultados. Es importante la realización de dos pruebas serológicas y una molecular para identificar a los portadores del virus de la hepatitis B y evitar su transmisión.


Assuntos
Doadores de Sangue , DNA Viral/sangue , Antígenos de Superfície da Hepatite B/sangue , Vírus da Hepatite B/genética , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Biomarcadores/sangue , Bancos de Sangue , Doadores de Sangue/estatística & dados numéricos , Portador Sadio/diagnóstico , Portador Sadio/virologia , Equador , Ensaio de Imunoadsorção Enzimática/métodos , Vírus da Hepatite B/imunologia , Humanos
5.
Gac. méd. Méx ; Gac. méd. Méx;157(1): 37-42, ene.-feb. 2021. tab
Artigo em Espanhol | LILACS | ID: biblio-1279071

RESUMO

Resumen Introducción: La identificación de portadores del virus de la hepatitis B en donantes de sangre es imperativo para evitar la transmisión de la enfermedad a través de transfusiones sanguíneas. Objetivo: Determinar si los donantes de sangre con resultados positivos de los marcadores serológicos HbsAg y anti-HBc eran portadores de ADN del virus de la hepatitis B. Métodos: Se recolectaron 12 745 muestras de seis bancos de sangre ecuatorianos, las cuales fueron analizadas con pruebas serológicas para identificar los marcadores infecciosos HBsAg, anti-HBc, anti-HBs mediante prueba ELISA automatizada. Todas las muestras positivas para uno, dos o los tres marcadores fueron analizadas con técnica molecular para determinar la presencia de ADN viral. Resultados: Se identificó que 27.5 % de las muestras reactivas solo a anti-HBc y 100 % de las muestras con resultados positivos de HBsAg/anti-HBc-IgM/IgG presentaron ADN del virus de la hepatitis B (p = 0.001). Conclusiones: La elección de los marcadores de infección y los métodos de detección definen los resultados. Es importante la realización de dos pruebas serológicas y una molecular para identificar a los portadores del virus de la hepatitis B y evitar su transmisión.


Abstract Introduction: Identification of hepatitis B virus carriers in blood donors is imperative in order to avoid transmission of the disease via blood transfusion. Objective: To determine if blood donors with positive results for serological markers HBsAg and anti-HBc were hepatitis B virus DNA carriers. Methods: 12,745 samples were collected from six Ecuadorian blood banks and analyzed for HBsAg, anti-HBc and anti-HBs infectious markers by automated ELISA. All samples that tested positive for one, two or all three markers were analyzed with molecular techniques to determine the presence of viral DNA. Results: 27.5 % of the samples that were reactive for anti-HBc alone and 100 % of those with positive results for HbsAg and IgM/IgG anti-HBc were identified to contain hepatitis B virus DNA (p = 0.001). Conclusions: The selection of infection markers, as well as the detection methods define the results. Performing two serological and one molecular test is important in order to identify hepatitis B virus carriers and prevent its transmission.


Assuntos
Humanos , Doadores de Sangue/estatística & dados numéricos , DNA Viral/sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Vírus da Hepatite B/genética , Antígenos de Superfície da Hepatite B/sangue , Bancos de Sangue , Ensaio de Imunoadsorção Enzimática/métodos , Biomarcadores/sangue , Portador Sadio/diagnóstico , Portador Sadio/virologia , Vírus da Hepatite B/imunologia , Equador
6.
Transfus Med ; 30(5): 396-400, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32250006

RESUMO

OBJECTIVES: To identify blood donors with occult hepatitis B infections (OBIs), determine the prevalence of antibody to hepatitis B core antigen (anti-HBc) positivity and estimate the impact of anti-HBc screening on donor deferral at CETS-Veracruz (Mexico). BACKGROUND: Hepatitis B virus infection is a major concern in transfusion medicine. Mexican regulations only mandate screening for hepatitis B surface antigen (HBsAg), and there are no requirements regarding testing for anti-HBc or use of a nucleic acid test (NAT). There is, therefore, limited information about the prevalence of anti-HBc positivity and occult hepatitis B among blood donors in Mexico. METHODS: This retrospective study examined individuals who donated blood to CETS-Veracruz from June 2014 to June 2017. All donors were serologically examined according to Mexican health regulations, and the prevalence of anti-HBc positivity was determined. A NAT was used to identify individuals with OBIs. RESULTS: We analysed the data of 28 016 blood donors. Over 4 years, the average prevalence of anti-HBc positivity was 1.05%. The risk factors for anti-HBc positivity were low education and age over 50 years. There were nine donors with OBIs. CONCLUSION: The presence of donors with OBIs in CETS-Veracruz and other Mexican blood banks highlights the need to mandate the implementation of anti-HBc screening in Mexico.


Assuntos
Bancos de Sangue , Doadores de Sangue , Hepatite B , Adolescente , Adulto , Fatores Etários , Feminino , Hepatite B/sangue , Hepatite B/epidemiologia , Anticorpos Anti-Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Humanos , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Fatores Socioeconômicos
7.
Colloids Surf B Biointerfaces ; 172: 272-279, 2018 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-30173094

RESUMO

An electrochemical immunosensor devoted the core hepatitis B antibody detection, based on polytyramine (PTy) and carbon nanotubes (CNT) composite was developed. The antibody interactions with immobilized antigens were detected by reduction on the electron transfer from ionic species coming from reactive amine groups of PTy. The synthesis in acid medium of PTy-CNT composite favorite a great amount of NH3+ ionic species, forming a nanocomposite with high catalytic activity on the electrode surface. As proof-of-concept, antibodies against the core hepatitis B virus were label-free and reagentless electrochemically detected by square wave voltammetry (SWV) through decrease on cathodic peaks. It was recently reported that hepatitis B core antigen antibodies (anti-HBc) is a powerful biomarker for hepatitis B virus (HBV) infection, being more specific than HBsAg due to the possibility of detecting the occult HBV infections. The nanostructured film was characterized by atomic force microscopy and electrochemical techniques. This immunosensor showed linear responses from 1.0 to 5.0 ng mL-1 and a limit of detection of 0.89 ng mL-1 anti-HBc. It was also tested in assays with negative and positive blood samples using 0.1 M KCl as electrolyte support on readings showing specific responses. This easy reagentless detection platform, showing a remarkable potential to development of bolder and simpler HBV assay for screening of blood bags, in attempting to circumvent point-of-care testing limitations.


Assuntos
Técnicas Eletroquímicas/métodos , Anticorpos Anti-Hepatite B/imunologia , Antígenos do Núcleo do Vírus da Hepatite B/análise , Eletrodos , Anticorpos Anti-Hepatite B/sangue , Antígenos do Núcleo do Vírus da Hepatite B/sangue , Humanos , Imunoensaio , Indicadores e Reagentes , Microscopia de Força Atômica , Nanotubos de Carbono/química , Espectroscopia de Infravermelho com Transformada de Fourier , Coloração e Rotulagem , Tiramina/química
8.
Rev. cuba. med. trop ; 68(3): 179-190, sep.-dic. 2016. ilus, tab
Artigo em Espanhol | CUMED | ID: cum-67450

RESUMO

Introducción: la infección oculta por el virus de la hepatitis B se caracteriza por la presencia en suero o plasma del genoma viral y anticuerpos contra la proteína de la cápsida (anti-HBc) en ausencia del marcador de infección.Objetivos: detectar la IOB en los pacientes hemodializados e identificar la posible relación de la IOB con la infección por el virus de la hepatitis C y variables sociodemográficas y epidemiológicas.Métodos: se estudiaron 709 muestras de pacientes provenientes de 18 unidades de hemodiálisis de Cuba. Se determinaron marcadores de infección, exposición e inmunidad al virus de la hepatitis B. Las muestras con HBsAg negativo, anti-HBc positivo y niveles de anti-HBs < 50 UI/L se les analizó la detección de ADN del virus de la hepatitis B y marcadores de lvirus de la hepatitis C.Resultados: las prevalencias de la infección y la exposición al virus de la hepatitis B fueron de 6,9 por ciento y 28,6 por ciento, respectivamente. El 4,3 por ciento de las muestras tuvieron criterio de infección oculta por el virus de la hepatitis B ; esta se detectó en el 58,1 por ciento (18/31) de los casos, con cargas virales menores de 105 UI/mL. La prevalencia global de infección oculta por el virus de la hepatitis B fue de 2,5 por ciento (18/709). No se encontró asociación significativa entre las variables analizadas.Conclusiones: la infección oculta por el virus de la hepatitis B fue frecuente en pacientes hemodializados con bajos niveles de anti-HBs, principalmente en aquellos con concentraciones no protectoras. Este estudio ratifica la necesidad de mantener la estrategia de prevención contra las hepatitis virales de transmisión parenteral en las unidades de diálisis(AU)


Introduction: occult hepatitis B virus infection is characterized by the presence of the viral genome and antibodies to the capside protein in serum or plasma (anti-HBc) that test negative for the infection marker.Objectives: to detect the occult hepatitis B virus in hemodialysis patients and to identify the possible relationship between occult hepatitis B infection and hepatitis C virus infection and the epidemiological and demographic variables.Methods: seventy thousand and nine serum samples from patients treated in 18 hemodialysis units were included. Serological markers for HBV infection, exposure and immunity were tested. Samples with negative HBsAg , positive anti-HBc and anti-HBs titers <50 IU/L were tested for detection of HBV-DNA and HCV markers.Results: the prevalence of HBV infection and exposure were 6.9 percent and 28.6 percent respectively. In the group, 4.3 percent of samples met occult hepatitis B infection criteria, the HBV-DNA was detected in 58.1 percent (18/31) of the samples, with viral loads below 105 IU/mL. Overall occult hepatitis B infection prevalence was 2.5 percent (18/709). There was no significant association among the analyzed variables.Conclusions: occult hepatitis B infection was frequent in hemodialysis patients with low levels of anti-HBs mainly in those with non protected titers. This study supports the need of keeping the prevention strategies against parenterally transmitted viral hepatitis in dialysis units(AU)


Assuntos
Humanos , Vírus da Hepatite B , Diálise Renal/métodos , Cuba
9.
Rev. cuba. med. trop ; 68(3): 179-190, sep.-dic. 2016. ilus, tab
Artigo em Espanhol | LILACS, CUMED | ID: biblio-844990

RESUMO

Introducción: la infección oculta por el virus de la hepatitis B se caracteriza por la presencia en suero o plasma del genoma viral y anticuerpos contra la proteína de la cápsida (anti-HBc) en ausencia del marcador de infección.Objetivos: detectar la IOB en los pacientes hemodializados e identificar la posible relación de la IOB con la infección por el virus de la hepatitis C y variables sociodemográficas y epidemiológicas.Métodos: se estudiaron 709 muestras de pacientes provenientes de 18 unidades de hemodiálisis de Cuba. Se determinaron marcadores de infección, exposición e inmunidad al virus de la hepatitis B. Las muestras con HBsAg negativo, anti-HBc positivo y niveles de anti-HBs < 50 UI/L se les analizó la detección de ADN del virus de la hepatitis B y marcadores de lvirus de la hepatitis C.Resultados: las prevalencias de la infección y la exposición al virus de la hepatitis B fueron de 6,9 por ciento y 28,6 por ciento, respectivamente. El 4,3 por ciento de las muestras tuvieron criterio de infección oculta por el virus de la hepatitis B ; esta se detectó en el 58,1 por ciento (18/31) de los casos, con cargas virales menores de 105 UI/mL. La prevalencia global de infección oculta por el virus de la hepatitis B fue de 2,5 por ciento (18/709). No se encontró asociación significativa entre las variables analizadas.Conclusiones: la infección oculta por el virus de la hepatitis B fue frecuente en pacientes hemodializados con bajos niveles de anti-HBs, principalmente en aquellos con concentraciones no protectoras. Este estudio ratifica la necesidad de mantener la estrategia de prevención contra las hepatitis virales de transmisión parenteral en las unidades de diálisis(AU)


Introduction: occult hepatitis B virus infection is characterized by the presence of the viral genome and antibodies to the capside protein in serum or plasma (anti-HBc) that test negative for the infection marker.Objectives: to detect the occult hepatitis B virus in hemodialysis patients and to identify the possible relationship between occult hepatitis B infection and hepatitis C virus infection and the epidemiological and demographic variables.Methods: seventy thousand and nine serum samples from patients treated in 18 hemodialysis units were included. Serological markers for HBV infection, exposure and immunity were tested. Samples with negative HBsAg , positive anti-HBc and anti-HBs titers <50 IU/L were tested for detection of HBV-DNA and HCV markers.Results: the prevalence of HBV infection and exposure were 6.9 percent and 28.6 percent respectively. In the group, 4.3 percent of samples met occult hepatitis B infection criteria, the HBV-DNA was detected in 58.1 percent (18/31) of the samples, with viral loads below 105 IU/mL. Overall occult hepatitis B infection prevalence was 2.5 percent (18/709). There was no significant association among the analyzed variables.Conclusions: occult hepatitis B infection was frequent in hemodialysis patients with low levels of anti-HBs mainly in those with non protected titers. This study supports the need of keeping the prevention strategies against parenterally transmitted viral hepatitis in dialysis units(AU)


Assuntos
Humanos , Vírus da Hepatite B/isolamento & purificação , Diálise Renal/efeitos adversos , Hepatite B/epidemiologia , Epidemiologia Descritiva , Estudos Transversais , Hepatite C/sangue , Cuba
10.
Hum Vaccin Immunother ; 12(7): 1857-62, 2016 07 02.
Artigo em Inglês | MEDLINE | ID: mdl-27171749

RESUMO

Although preventable with vaccination, Hepatitis B virus (HBV) infection is a major health concern, with ∼400 million people at risk of developing the chronic form of the disease worldwide. The anti-HBV vaccine consists of a recombinant HBV surface antigen (HBsAg), which induces specific anti-HBs antibodies and confers 95% protection for >20 y. The aim of the present study was to analyze the response to HBV vaccination by measuring anti-HBs antibodies in serum samples from medical students of a public university in Puebla, Mexico. HBV infection markers HBsAg and anti-HBs, were also determined. A total of 201 students were included and vaccination coverage was found at 54%. Overall seropositivity for HBsAg, anti-HBc and anti-HBs determined by ELISA was 0.5%, 1.0% and 47%, respectively. Protective levels of anti-HBs >10 mIU/mL were found in 93.2% of subjects vaccinated with 2 or 3 doses and in 40% of those vaccinated with a single dose; while only 4.8% of unvaccinated subjects were anti-HBs positive. The response to the HBV vaccine was different in each participant, despite similar vaccination scheme. A history of blood transfusion/organ transplant or more than 2 sexual partners was significantly associated with anti-HBc positivity, OR = 399 (p = 0.010) and OR = 19.9 (p = 0.044), respectively. HBV immunization coverage was low in our sample compared with reports from countries with similar HBV prevalence, but anti-HBs in vaccinated individuals were in the expected range. It is important to promote HBV vaccination and awareness among medical students, due to their exposure risk.


Assuntos
Anticorpos Anti-Hepatite B/sangue , Antígenos de Superfície da Hepatite B/imunologia , Vírus da Hepatite B/imunologia , Estudantes de Medicina , Adolescente , Adulto , Feminino , Antígenos do Núcleo do Vírus da Hepatite B/imunologia , Humanos , Masculino , México , Estudos Soroepidemiológicos , Universidades , Adulto Jovem
11.
J Med Virol ; 88(4): 639-46, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26381185

RESUMO

HBV-HIV coinfection is prevalent. Frequently, anti-HBc is the only serological marker of HBV, which can be indicative of HBV resolved infection, when found together with anti-HBs reactivity; or present as "isolated anti-HBc," related to HBV occult infection with presence of detectable DNA HBV, more prevalent in HIV-positive individuals. Regional data about this condition are scarce. Anti-HBc rapid test has been used as screening, but its performance has not been described in HIV-positive patients. The aim of this study was determine prevalence of anti-HBc in HIV-positive patients, serological pattern of HBV resolved infection and isolated anti-HBc, evaluating presence of HBV occult infection. Assess anti-HBc rapid test compared to ECLIA. Methods included measurement of anti-HBc and anti-HBs in HIV-positive patients with negative HBsAg. Serum HBV DNA quantification and HBV booster vaccination to "isolated anti-HBc" individuals. Detection of anti-HBc by rapid test and ECLIA. In 192 patients, prevalence of anti-HBc was 42.7% (82/192); associated to male gender, drug use, men-sex-men, positive-VDRL, and longer time HIV diagnosis. 34.4% (66/192) had presence of anti-HBs, mean titers of 637 ui/ml. Isolated anti-HBc in 8.3% (16/192), associated to detectable HIV viral load and no-use of HAART; in them, HBV DNA was undetectable, and 60% responded to HBV vaccination booster. Anti-HBc rapid test showed low sensibility (32.9%) compared to ECLIA. These results show that prevalence of anti-HBc in HIV-positive individuals is high, in most cases accompanied with anti-HBs as HBV resolved infection. Low prevalence of "isolated anti-HBc," with undetectable HBV DNA, and most had anamnestic response to HBV vaccination; suggest low possibility of occult HBV infection. Anti-HBc rapid test cannot be recommended as screening method for anti-HBc.


Assuntos
Infecções por HIV/complicações , Anticorpos Anti-Hepatite B/sangue , Antígenos do Núcleo do Vírus da Hepatite B/imunologia , Antígenos de Superfície da Hepatite B/sangue , Vírus da Hepatite B/imunologia , Hepatite B/epidemiologia , Hepatite B/imunologia , Adulto , Portador Sadio/virologia , Chile/epidemiologia , Feminino , Hepatite B/virologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Adulto Jovem
12.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;48(5): 524-531, Sept.-Oct. 2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-763325

RESUMO

ABSTRACTINTRODUCTION:Since women are frequently the minority among blood donors worldwide, studies evaluating this population usually reflect male features. We assessed the features of female blood donors with positive serology for HBV and compared them with those of men.METHODS The study comprised consecutive blood donors referred to a specialized liver disease center to be evaluated due to HBsAg- and/or anti-HBc-positive tests.RESULTS: The study encompassed 1,273 individuals, 219 (17.2%) of whom were referred due to positive HBsAg test and 1,054 (82.8%) due to reactive anti-HBc test. Subjects' mean age was 36.8±10.9 years, and 28.7% were women. Female blood donors referred for positive HBsAg screening tests demonstrated higher prevalence of healthcare workers (9.3% vs 2.5%) and lower prevalence of sexual risk behaviors (15.1% vs 41.1%) and alcohol abuse (1.9% vs 19.8%) compared to men. Women had lower ALT (0.6 vs 0.8×ULN), AST (0.6 vs 0.8×ULN), direct bilirubin (0.2 vs 0.3mg/dL), and alkaline phosphatase (0.5 vs 0.6×ULN) levels and higher platelet count (223,380±50,293 vs 195,020±53,060/mm3). Women also had a higher prevalence of false-positive results (29.6% vs 17.0%). No differences were observed with respect to liver biopsies. Female blood donors referenced for reactive anti-HBc screening tests presented similar clinical, epidemiological, and biochemical characteristics to those reported for positive HBsAg screening tests and similarly had a higher prevalence of false-reactive results.CONCLUSIONS: Compared to men, female blood donors with positive HBsAg and/or anti-HBc screening tests demonstrated higher prevalence of professional risk and false-positive results and reduced alteration of liver chemistry.


Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doadores de Sangue/estatística & dados numéricos , Hepatite B/epidemiologia , Brasil/epidemiologia , Métodos Epidemiológicos , Reações Falso-Positivas , Anticorpos Anti-Hepatite B/sangue , Antígenos do Núcleo do Vírus da Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Vírus da Hepatite B/imunologia , Hepatite B/diagnóstico , Imunoglobulina M/sangue , Fatores Sexuais
13.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;48(3): 258-264, May-Jun/2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-749874

RESUMO

INTRODUCTION: Occult hepatitis B infection (OBI) is considered to be one of the major risks for patients suffering from end-stage renal disease (ESRD) on regular hemodialysis (HD) and patients with chronic hepatitis C virus (HCV) infection. This study compared the prevalence of OBI among these two high-risk groups in the Suez Canal region, Northeastern Egypt, to obtain a better national overview of the magnitude of OBI in this region. METHODS: Serum samples were collected from 165 HD patients and 210 chronic HCV-infected patients. Anti-HCV antibody, hepatitis B surface antigen (HBsAg), total hepatitis B core (anti-HBc) antibody, and hepatitis B surface antibody (anti-HBs) were detected by enzyme-linked immunosorbent assay (ELISA). HCV RNA was detected using a quantitative real-time RT-PCR assay, and HBV was detected using a nested PCR. RESULTS: All patients were negative for HBsAg. A total of 49.1% and 25.2% of the patients in the HD and HCV groups, respectively, were anti-HBc-positive. In addition, more anti-HBs-positive patients were detected in the HD group compared to the HCV group (52.1% and 11.4%, respectively). Three cases were positive for HBV DNA in the HD group, while eighteen positive cases were detected in the HCV group. Both study groups showed significant differences in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level as well as anti-HBc, anti-HBs and HBV-DNA positivity. CONCLUSIONS: OBI was more prevalent among chronic HCV patients than HD patients in the Suez Canal region, Egypt, with rates of 8.5% and 1.8%, respectively. However, more precise assessment of this infection requires regular patient follow-up using HBV DNA detection methods. .


Assuntos
Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Hepatite B/epidemiologia , Hepatite C Crônica/epidemiologia , Diálise Renal/estatística & dados numéricos , DNA Viral/análise , Ensaio de Imunoadsorção Enzimática , Egito/epidemiologia , Anticorpos Anti-Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Vírus da Hepatite B/genética , Vírus da Hepatite B/imunologia , Hepatite B/complicações , Hepatite B/diagnóstico , Hepatite C Crônica/complicações , Falência Renal Crônica/terapia , Reação em Cadeia da Polimerase , Prevalência , Diálise Renal/efeitos adversos
14.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;45(2): 260-262, Mar.-Apr. 2012. ilus
Artigo em Inglês | LILACS | ID: lil-625185

RESUMO

INTRODUCTION: It is known that the hepatitis B (HB) vaccine is effective, but it is alarming that sudden drops of antibody levels may coincide with the onset of adolescence. METHODS: Antibody levels against HB vaccine surface antigen (anti-HBs) and HB vaccine core antigen (anti-HBc) were measured on the blood samples of children with a mean age of 11.4 years. RESULTS: About 54.8% had protective levels of anti-HBs. Of those who were anti-HBc-positive (4.4%), an average of 218.4 anti-HBs mIU/mL was found. CONCLUSIONS: Immunological protection was found in the majority of children. However, more studies are needed to elucidate the heritability of nonresponders and establish strategies against such events.


INTRODUÇÃO: Sabe-se que a vacina contra a hepatite B é eficaz, mas é preocupante que quedas bruscas nos níveis de anticorpos possam coincidir com o início da adolescência. MÉTODOS: Níveis de anticorpos anti-HBs e anti-HBc foram medidos nas amostras de sangue de crianças com idade média de 11,4 anos. RESULTADOS: Cerca de 54,8% apresentaram níveis protetores de anti-HBs. Dos que apresentaram anti-HBc positivo (4,4%), uma média de anti-HBs de 218,4mUI/mL foi encontrada. CONCLUSÕES: Proteção imunológica foi encontrada na maioria das crianças. No entanto, mais estudos são necessários para elucidar a herança de não-respondedores e estabelecer estratégias contra tais acontecimentos.


Assuntos
Criança , Feminino , Humanos , Masculino , Anticorpos Anti-Hepatite B/sangue , Antígenos do Núcleo do Vírus da Hepatite B/imunologia , Antígenos de Superfície da Hepatite B/imunologia , Vacinas contra Hepatite B/imunologia , Hepatite B/prevenção & controle , Anticorpos Anti-Hepatite B/imunologia , Vacinas contra Hepatite B/administração & dosagem , Hepatite B/imunologia , Fatores de Tempo
15.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;44(3): 269-273, May-June 2011. ilus, tab
Artigo em Inglês | LILACS | ID: lil-593349

RESUMO

INTRODUCTION: Positive serological tests for hepatitis viruses B and C at blood banks are an important reason for blood deferral. Additionally, high residual risk for transfusing hepatitis-contaminated blood has been estimated in southern Brazil. This study aimed to identify risk factors for positive serological tests for viral hepatitis (VH) in blood donors (BD). METHODS: A case-control study included consecutive BD with positive serology for VH, between 2008 and 2009. Cases and controls (BD with negative serology for VH) were paired 1:1 by sex and donation date. Assessment of clinical and epidemiological characteristics related to viral hepatitis was conducted. RESULTS: Among 1,282 blood donors (641 cases and 641 controls), those with positive serology for viral hepatitis had higher mean age (p<0.001); higher proportion of replacement donation (p<0.001); first donation (p<0.001); and interviewer deferment (p=0.037), compared to controls. Furthermore, donors with positive tests were less regular donors (p<0.001), had less previous history of rejection (p=0.003) and showed lower hematocrit median before donation (p=0.019). Multivariate analysis demonstrated that age (OR=1.056, 95 percentCI 1.042-1.069, p<0.001), replacement donation (OR=1.545, 95 percentCI 1.171-2.038, p=0.002) and first donation (OR=9.931, 95 percentCI 7.486-13.173, p<0.001) were independently associated with positivity of serological tests for viral hepatitis. CONCLUSIONS: Specific characteristics of blood donors were associated with positive serology for viral hepatitis. These peculiarities should be taken into account when assessing candidates for blood donation.


INTRODUÇÃO: Testes sorológicos positivos para os vírus de hepatites B e C nos bancos de sangue são importante causa de descarte de bolsas de sangue. Além disso, estima-se um alto risco residual de transfundir sangue contaminado com vírus de hepatite no sul do Brasil. Este estudo objetiva identificar fatores de risco para sorologias positivas para hepatites virais (HV) em doadores de sangue (DS). MÉTODOS: Estudo caso-controle que incluiu, consecutivamente, DS com sorologias positivas para HV entre 2008 e 2009. Casos e controles (DS com sorologias negativas para HV) foram pareados 1:1 de acordo com gênero e data da doação. RESULTADOS: Entre 1.282 doadores de sangue incluídos (641 casos e 641 controles), aqueles positivos para HV, quando comparados aos controles, apresentaram maior média de idade (p<0,001), maior proporção de doações direcionadas (p<0,001), primeira doação (p<0,001) e recusa pelo entrevistador (p=0,037). Outrossim, doadores positivos eram, com menos frequência, doadores regulares de sangue (p<0,001), apresentavam menos história prévia de rejeição na doação (p=0,003) e evidenciaram menor mediana de hematócrito (p=0,019). Análise multivariada demonstrou que idade (OR=1,056; IC95 por cento 1,042-1,069; p<0,001), doação direcionada (OR=1,545; IC95 por cento 1,171-2,038; p=0,002) e primeira doação (OR=9,931; IC95 por cento 7,486-13,173; p<0,001) foram independentemente associadas a testes positivos para HV. CONCLUSÕES: Características específicas de DS foram associadas com sorologias positivas para HV. Estas peculiaridades devem ser levadas em consideração na avaliação de candidatos a doação de sangue.


Assuntos
Adulto , Feminino , Humanos , Masculino , Doadores de Sangue , Anticorpos Anti-Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Hepatite B/diagnóstico , Anticorpos Anti-Hepatite C/sangue , Hepatite C/diagnóstico , Brasil/epidemiologia , Estudos de Casos e Controles , Estudos Transversais , Hepatite B/epidemiologia , Hepatite C/epidemiologia , Fatores de Risco , Fatores Socioeconômicos
16.
Salud pública Méx ; 53(supl.1): S26-S31, 2011. ilus, tab
Artigo em Inglês | LILACS | ID: lil-597120

RESUMO

OBJECTIVE: To study the distribution of the hepatitis B antibody (anti-HBc) based on a national serosurvey from 10 Mexican states showing a mean HBV prevalence higher than the national one. MATERIALS AND METHODS: This was a cross-sectional study. During 2003, anti-HBc was analyzed at INSP in 19 907 sera, and the related sociodemographic factors were determined. RESULTS: Anti-HBc prevalence was greater among men, but it was also associated to age, residence in a rural area, low socio-economic status, and illiteracy. Clusters of very high anti-HBc prevalence were found in several rural communities where the prevalence of anti-HBc in adults is 3 to 20 times the national average. CONCLUSIONS: Besides a low endemicity of HBV in Mexico, distribution is heterogeneous as was shown in several of the states studied, where there are rural towns with very high prevalence of HBV markers. National serosurveys are useful tools for identifying communities with hepatitis B hyperendemicity, where focused research and control measures are needed.


OBJETIVO: Estudiar la distribución de anti-HBc en 10 estados con prevalencia mayor a la media nacional en la ENSA 2000. MATERIAL Y MÉTODOS: Durante 2003 se analizó en el INSP anti-HBc en 19 907 muestras de suero, se determinaron factores sociodemográficos relacionados. RESULTADOS: La prevalencia de anti-HBc fue mayor en hombres. Se asoció con la edad, residencia en áreas rurales, bajo nivel socioeconómico y analfabetismo. Se encontraron agrupamientos de alta prevalencia de anti-HBc en comunidades rurales en las cuales la prevalencia de anti-HBc en adultos está entre 3 y 20 veces por arriba de la media nacional. CONCLUSIONES: Contrastando con la baja endemicidad del VHB en México, su distribución es heterogénea. En varios estados se hallaron localidades rurales con muy alta prevalencia de anti-HBc. Las encuestas de salud permiten identificar comunidades donde la hepatitis B es hiperendémica y en las cuales se requiere enfocar la investigación y tomar medidas de control.


Assuntos
Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Anticorpos Anti-Hepatite B/sangue , Biomarcadores , Análise por Conglomerados , Estudos Transversais , Escolaridade , Hepatite B/epidemiologia , México/epidemiologia , Fatores de Risco , População Rural , Estudos de Amostragem , Estudos Soroepidemiológicos , Classe Social
17.
Salud pública Méx ; 53(supl.1): S32-S36, 2011. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-597121

RESUMO

OBJETIVO: Determinar la prevalencia de hepatitis B, C, y VIH en una muestra ampliada de dos de las comunidades rurales en las que se registró la mayor prevalencia de anticuerpos anti-core del virus de la hepatitis (anti-HBc) en la Encuesta Nacional de Salud 2000 (ENSA 2000). MATERIAL Y MÉTODOS: Se realizó un estudio transversal en las comunidades de La Calera y Cuambio, dos poblaciones rurales adyacentes del municipio de Zirándaro, Guerrero, seleccionadas por mostrar muy alta prevalencia de anti-HBc en la ENSA 2000. Se determinó la prevalencia de marcadores séricos de hepatitis B y C, y VIH, así como factores sociodemográficos asociados entre los habitantes mayores de 10 años. RESULTADOS: Se confirmó una muy alta prevalencia de marcadores de hepatitis B, asociada con la edad, baja escolaridad y relaciones con trabajadoras sexuales en Estados Unidos, mientras que la prevalencia de hepatitis C fue baja y no se detectó ningún caso de VIH. CONCLUSIONES: Existen en México comunidades rurales con alta endemicidad de hepatitis B, en las cuales es conveniente profundizar la investigación de determinantes de la transmisión de este virus. Estas comunidades son identificadas con certeza por las encuestas nacionales de salud.


OBJECTIVE: To perform a hepatitis B, C, and HIV survey in an enhanced sample from two rural communities with the highest anti-HBc prevalence found in ENSA 2000. MATERIALS AND METHODS: This was a cross-sectional study.We studied the communities of La Calera and Cuambio, two adjacent rural towns of the district of Zirándaro, Guerrero, targeted because of the high prevalence of anti-HBc shown in ENSA 2000.We assessed the prevalence of hepatitis B and C, and HIV serological markers and associated factors among inhabitants older than 10 years. RESULTS: A very high prevalence of hepatitis B markers associated with socioeconomic factors was confirmed, while hepatitis C prevalence was low and HIV absent in the two communities addressed. CONCLUSIONS: National serosurveys are an accurate tool for identifying communities with hepatitis B high endemicity where focused research and control measures are needed.


Assuntos
Adolescente , Adulto , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , HIV-1 , Anticorpos Anti-HIV/sangue , Infecções por HIV/epidemiologia , Anticorpos Anti-Hepatite B/sangue , Hepatite B/epidemiologia , Anticorpos Anti-Hepatite C/sangue , Hepatite C/epidemiologia , Inquéritos Epidemiológicos , México/epidemiologia , Fatores de Risco , População Rural , Estudos Soroepidemiológicos , Fatores Socioeconômicos
18.
Braz. j. infect. dis ; Braz. j. infect. dis;14(1): 60-65, Jan.-Feb. 2010. tab
Artigo em Inglês | LILACS | ID: lil-545009

RESUMO

Hepatitis B and C are important causes of morbidity and mortality worldwide. In Brazil, according to the Ministry of Health, about 15 percent of population is infected by hepatitis B virus (HBV) and less than 1 percent by hepatitis C virus (HCV). Nevertheless, the age-specific prevalence of HBV and HCV markers remains unknown. This study aimed to determine the seroprevalence of HBV and HCV markers of infection and immunity in children and adolescents between 10 to 16 years old who live in the metropolitan area of Florianópolis, state of Santa Catarina, South of Brazil. Three hundred and eighty four individuals were enrolled in this study. Serological markers for HBV and HCV (HBsAg, total anti-HBc, anti-HBc IgM, anti-HBs and anti-HCV) were determined through Microparticle Enzyme Immunosorbant Assay (MEIA) - AxSYM System® - by using commercial diagnostic kits (Abbott Laboratories, Abbott Park, Illinois, USA). All 384 adolescents (100 percent) were negative for HBsAg and anti-HBc IgM. Only two (0.52 percent) were positive for total anti-HBc. Among the studied individuals, 226 (58.85 percent) presented titers of anti-HBs > 10.0mIU/mL, 121 (31.51 percent) presented anti HBs < 10.0mIU/mL, and 37 (9.64 percent) did not present titers of anti-HBs. Regarding to anti-HCV, all 384 adolescents (100 percent) presented negative results for this marker. In conclusion, this study showed a low prevalence of HBV and HCV infections. In addition, it was verified a great number of children and adolescents (89.84 percent) who were positive for the immunity marker anti-HBs, implying that the National Immunization Program Protocol for hepatitis B has been effective in the studied region.


Assuntos
Adolescente , Criança , Feminino , Humanos , Masculino , Hepacivirus/imunologia , Vírus da Hepatite B/imunologia , Hepatite B/epidemiologia , Hepatite C/epidemiologia , Biomarcadores/sangue , Brasil/epidemiologia , Antígenos do Núcleo do Vírus da Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Hepatite B/diagnóstico , Anticorpos Anti-Hepatite C/sangue , Hepatite C/diagnóstico , Imunoglobulina M/sangue , Estudos Soroepidemiológicos , População Urbana
19.
Rev. bras. anal. clin ; 42(4): 269-272, 2010. tab, graf
Artigo em Português | LILACS | ID: lil-579394

RESUMO

Para determinar a presença do perfil sorológico sugestivo de hepatite B oculta, fora, analisados os marcadores HBsAg e os anticorpos anti-HBc e anti-HBs de 7896 doadores de sangue do Banco de Sangue do Hospital Universitário de Santa Maria - RS, no período de abril de 2007 a agosto de 2008. Foi estimada uma prevalência de 0,86% para o marcador anti-HBc, sendo este marcador o único detectado em 0,11% dos indivíduos estudados. Tentar esclarecer e orientar o acompanhamento destes pacientes é importante para iniciar tratamento adequado, se necessário, ou evitar que estes indivíduos se tornem ansiosos com a possibilidade de serem portadores de doença infecciosa crônica.


Assuntos
Doadores de Sangue , Anticorpos Anti-Hepatite B
20.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 7(1): 5-12, jun. 2009. tab
Artigo em Espanhol | LILACS | ID: lil-538199

RESUMO

El objetivo de este trabajo es determinar si las transaminasas hepáticas tienen valor como pruebas complementarias que orienten el diagnóstico de hepatitis B y C, en donantes de sangre con anticuerpos positivos por el método ELISA a estas infecciones virales; teniendo en cuenta que las pruebas confirmatorias como el inmunoensayo recombinante (RIBA) o la prueba de ácidos nucleicos por técnicas moleculares como PCR (RNA HCV) para hepatitis C y DNA viral (PCR) para hepatitis B no se realizan aún en nuestro país debido a sus elevados costos. Se busca sumar esfuerzos en salud pública desde los bancos de sangre debido a la trascendencia de llegar a un diagnóstico en los donantes seropositivos, que hayan sido captados en el tamizaje, para prevenir la propagación de estas hepatitis. Se realizaron pruebas serológicas para hepatitis C, anticuerpos frente al antígeno del core de la hepatitis B y determinaciones de los niveles de GPT o ALT (Transaminasa Glutámica Pirúvica o Alanina Amino Transferasa), GOT o AST (Transaminasa Glutámico Oxalacética o Aspartato Amino Transferasa) en 236 donantes de sangre seropositivos para hepatitis B y C del Banco de Sangre del Hospital de Clínicas de la Universidad Nacional de Asunción-Paraguay. Las transaminasas elevadas fueron clasificadas de acuerdo a los marcadores serológicos positivos para hepatitis B y C, encontrándose niveles elevados en un 13.9% de individuos con anti-HBc, 40% en individuos con anti HCV y 2 de 7 casos en individuos con serología positiva para ambos marcadores serológicos. Casi la mitad de los donantes con marcador serológico positivo para anti HCV presentan elevación de las transaminasas.


The aim of this study was to determine if liver transaminases had value as complementary tests to orientate the diagnosis of hepatitis B and C in blood donors with positive antibody to these viral infections by the EIA method, considering that confirmatory tests such as the recombinant immunoassay (RIBA) or nucleic acid test by molecular techniques such as PCR (HCV RNA) for hepatitis C and viral DNA (PCR) for hepatitis B are not performed in our country due to their high costs. We are looking for joining efforts in public health from the blood banks due to the importance of reaching a diagnosis of seropositive donors who have been detected in the screening to prevent the spread of hepatitises. Serologic tests for hepatitis C, antibodies against the core antigen of hepatitis B and determinations of the levels of ALT or GPT (Alanine aminotransferase or Glutamic pyruvic transaminase), AST or GOT (Aspartate aminotransferase or Glutamic oxalacetic transaminase) were carried out in 236 blood donors seropositive for hepatitis B and C of the Blood Bank of the Hospital de Clinicas, National University of Asuncion, Paraguay. Elevated transaminases were classified according to the positive serological markers for hepatitis B and C finding high levels in 13.9% in donors with anti-HBc, 40% in donors with anti HCV and two of seven cases in donors with positive serology for both serological markers. Almost half of the donors with positive serologic marker for anti HCV had elevated transaminases.


Assuntos
Aspartato Aminotransferases , Bancos de Sangue , Doadores de Sangue , Anticorpos Anti-Hepatite B , Anticorpos Anti-Hepatite C
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA